Jay R. Luly
2018
In 2018, Jay R. Luly earned a total compensation of $4.5M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 5% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $355,688 |
---|---|
Option Awards | $2,684,490 |
Salary | $611,178 |
Stock Awards | $838,530 |
Other | $18,851 |
Total | $4,508,737 |
Luly received $2.7M in option awards, accounting for 60% of the total pay in 2018.
Luly also received $355.7K in non-equity incentive plan, $611.2K in salary, $838.5K in stock awards and $18.9K in other compensation.
Rankings
In 2018, Jay R. Luly's compensation ranked 2,343rd out of 14,244 executives tracked by ExecPay. In other words, Luly earned more than 83.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,343 | 84th |
Manufacturing | 859 | 85th |
Chemicals And Allied Products | 290 | 86th |
Drugs | 234 | 87th |
Pharmaceutical Preparations | 182 | 87th |
Luly's colleagues
We found four more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2018.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019